肾性贫血治疗指南ppt课件.pptVIP

肾性贫血治疗指南;;;CPR 1.1. IDENTIFYING PATIENTS AND INITIATING EVALUATION;贫血定义;CPR 1.2. EVALUATION OF ANEMIA IN CKD;贫血实验室检查内容;肾性贫血的检查流程;CPG AND CPR 2.1. HB RANGE; 2.1 HEMOGLOBIN TARGET 2007;rHuEPO 治疗肾性贫血靶目标值;CPR 3.1. USING ESAs;CPR 3.1. USING ESAs 3.1.2 ESA dosing;CPR 3.1. USING ESAs ;CPR 3.1. USING ESAs;rHuEPO 的临床应用;rHuEPO 的临床应用;rHuEPO 的临床应用;rHuEPO 的临床应用;不良反应;3.2. USING IRON AGENTS;3.2. USING IRON AGENTS;3.2. USING IRON AGENTS;3.2. USING IRON AGENTS;补充铁剂;铁状态评估;铁剂治疗的靶目标值;补充铁剂;口服铁剂;3.3. USING PHARMACOLOGICAL ANDNONPHARMACOLOGICAL ADJUVANTS TO ESA TREATMENT IN HD-CKD;3.4.: TRANSFUSION THERAPY;3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB;rHuEPO 治疗的低反应性（EPO 抵抗）;CPR 3.5. EVALUATING AND CORRECTING PERSISTENT FAILURE TO REACH OR MAINTAIN INTENDED HB;rHuEPO 抗体介导的纯红细胞再生障碍性贫血（PRCA）;长效ESA：;持续性促红细胞生成素受体激动剂(continuous erythropoietin receptor activator，CERA）;;Methods. Patients were randomized (1:1) to receive either 1.2 ?g/kg C.E.R.A. Q4W or darbepoetin alfa QW/Q2W during a 20-week correction period and an 8-week evaluation period. Results. The Hb response rate for C.E.R.A. was 94.1%, significantly higher than the protocol-specified 60% response rate and comparable with darbepoetin alfa. C.E.R.A. Q4W was non-inferior to darbepoetin alfa QW/Q2W, with similar mean Hb changes from baseline of 1.62 g/dL and 1.66 g/dL, respectively. Patients receiving C.E.R.A. showed a steady rise in Hb, with fewer patients above the target range during the first 8 weeks compared with darbepoetin alfa. Adverse event rates were comparable between the treatment groups. Conclusion. C.E.R.A. Q4W successfully corrects anaemia and maintains stable Hb levels within the recommended target range in non-dialysis CKD patients.;其他新型制剂;红细胞生成素受体激动剂肽治疗纯红细胞再生障碍性贫血;谢谢